ライフサイエンスコーパス: ROP

1 ROP experts were recruited in 2007 and 2016 to classify

2 ROP was induced in 21 rats then two concentrations of 2-

3 with the fellow eye being treated for type 1 ROP (2 eyes, 15.4%); concerning structural changes (9 ey

4 .7% in control group) and the rate of type 1 ROP (20.5% in case group and 4.7% for controls) were fou

5 The sensitivity for detecting type 1 ROP (32 infants) was 100% (95% CI, 89.3%-100%) with each

6 cted 452 of 459 infants who developed type 1 ROP (sensitivity, 98.5%; 95% CI, 96.9%-99.3%), reducing

7 Premature infants with type 1 ROP (subdivided into stage 3+ ROP and aggressive posteri

8 nfants who demonstrated recurrence of type 1 ROP after IVB monotherapy, including examination of RetC

9 eatment of Retinopathy of Prematurity type 1 ROP and potential reduction in the number of infants req

10 Lowering the cut point to capture all type 1 ROP cases (sensitivity, 100%; 95% CI, 99.2%-100%) result

11 was present at that examination, all type 1 ROP cases would be captured, and the number of examinati

12 ntial role of anti-VEGF treatment for type 1 ROP has become a focus in recent years, but the protract

13 ember 2016, 61 premature infants with type 1 ROP in 1 or both eyes were enrolled in a masked, multice

14 ction or sooner, and no recurrence of type 1 ROP or severe neovascularization requiring additional tr

15 abetes and the development of ROP and type 1 ROP, adjusting for multiple risk factors.

16 ean outcomes were the sensitivity for type 1 ROP, reductions in infants requiring imaging or examinat

17 atment in eyes with disease less than type 1 ROP.

18 pite a clinical diagnosis milder than type 1 ROP.

19 All inborn babies with type 1 zone 1 ROP at the Neonatal Intensive Care Unit of the Catholic

20 of 73 images independently classified by 11 ROP experts for validation.

21 AGING (trained reader grading of type 1 or 2 ROP initiates diagnostic examinations), and TARP (CHOP-R

22 osing AP-ROP (94% vs. 78%; P < 0.01), type 2 ROP or worse (92% vs. 84%; P = 0.04), and ROP requiring

23 preinjection plus disease or zone I stage 3 ROP by 5 days after injection or sooner, and no recurren

24 h early and same eyes, zone I and/or stage 3 ROP determined a significant proportion of RW-ROP; plus

25 40 (57.5%) agreed with readers that stage 3 ROP was present, and 4 of 16 (25.0%) agreed that plus di

26 es with referral-warranted (RW) ROP (stage 3 ROP, zone I ROP, plus disease) on diagnostic examination

27 ts with type 1 ROP (subdivided into stage 3+ ROP and aggressive posterior ROP [APROP]) in zone I or z

28 ch appeared at the following sites: stage 3+ ROP with confluent neovascularization recurred both at t

29 ver, APROP (6/6 infants [100%]) and stage 3+ ROP with nonconfluent neovascularization (2/14 infants [

30 action concerning for progression to stage 4 ROP (3 eyes, 23.1%); persistent ROP at an advanced postm

31 te analysis, having stage 5 ROP (vs. stage 4 ROP) and presence of lensectomy were found to be signifi

32 of 10 years of clinical ROP experience and 5 ROP publications, and 5 image graders (3 physicians and

33 ts who underwent LSV for stage 4A, 4B, and 5 ROP were retrospectively reviewed.

34 In univariate analysis, having stage 5 ROP (vs. stage 4 ROP) and presence of lensectomy were fo

35 ulsion in regressing neovascularization of a ROP rat model.

36 thod in reduction of neovascularization of a ROP rat model.

37 Indications for treatment included active ROP with the fellow eye being treated for type 1 ROP (2

38 oagulation for achieving regression of acute ROP.

39 These data confirm that acute ROP is typically symmetrical and supports within subject

40 Among 401 eyes with advanced ROP, 40 eyes (10.0%) had glaucoma during a mean of 3.06+

41 a suggests that caffeine may protect against ROP.

42 2 ROP or worse (92% vs. 84%; P = 0.04), and ROP requiring treatment (89% vs. 79%; P < 0.01) was bett

43 ide a founding framework revealing auxin and ROP signaling of inner polar nuclear position with some

44 ilar reaction rates for copolymerization and ROP and therefore to a terpolymer with a statistical com

45 fy the relationship between preeclampsia and ROP.

46 lysed, and also two different living anionic ROP methodologies have been developed: the latter permit

47 A adjusted odds ratios [ORs] of 2.46 for any ROP, 2.88 for stage 3, and 3.19 for RW-ROP).

48 P<0.0001), whereas the time of onset of any ROP did not vary (34.3 weeks CRYO, 34.1 weeks ETROP, 34.

49 The specificity for diagnosing AP-ROP (94% vs. 78%; P < 0.01), type 2 ROP or worse (92% vs

50 , category, and aggressive posterior ROP (AP-ROP).

51 ight the need for standardized approaches as ROP telemedicine becomes more widespread.

52 Because ROP telemedicine is used more widely, development of sta

53 s that are typically difficult to achieve by ROP of lactones.

54 dependent, auxin sensitive, and regulated by ROP signaling.

55 The original CHOP ROP model correctly predicted 452 of 459 infants who dev

56 hiladelphia Retinopathy of Prematurity (CHOP ROP) model uses birth weight (BW), gestational age at bi

57 Conclusion and Relevance: The CHOP ROP model demonstrated high but not 100% sensitivity and

58 To validate the CHOP ROP model in a multicenter cohort that is large enough t

59 In the primary analysis, the CHOP ROP model was applied weekly to predict the risk of ROP.

60 ic examinations by an ophthalmologist), CHOP-ROP (birth weight and gestational age, with weekly weigh

61 hiladelphia Retinopathy of Prematurity (CHOP-ROP) postnatal weight gain predictive model are 2 approa

62 tes diagnostic examinations), and TARP (CHOP-ROP alarm initiates imaging, and imaging finding of seve

63 242 infants had 877 examinations; with CHOP-ROP, 184 infants had 730 examinations; with e-ROP IMAGIN

64 each with a minimum of 10 years of clinical ROP experience and 5 ROP publications, and 5 image grade

65 d approach may reduce the number of clinical ROP interventions more than either approach alone.

66 r-eye agreements were found when considering ROP features at the first image session, at the last ima

67 care for ROP and suggests that a continuous ROP plus disease severity score may reflect more accurat

68 henyl)imino)-2-pentene) , for the controlled ROP of various OCAs without epimerization.

69 ional age (GA) decreased over time from CRYO-ROP (954 g [185 g], 27.9 weeks [2.2 weeks]) to ETROP (90

70 therapy for Retinopathy of Prematurity (CRYO-ROP) and Early Treatment for Retinopathy of Prematurity

71 of preterm infants with treatment-demanding ROP during a recent birth period (2003-2008).

72 ease in the incidence of treatment-demanding ROP over time in Denmark.

73 ociated with an increased risk of developing ROP among an unrestricted cohort but with a reduced risk

74 ed) varied (17.8% CRYO, 12.3% ETROP, 19.4% e-ROP; P<0.0001), whereas the time of onset of any ROP did

75 ing <750 g (15.8% CRYO, 24.9% ETROP, 33.4% e-ROP; P<0.0001).

76 ng Acute-Phase Retinopathy of Prematurity (e-ROP) Study and to evaluate their potential use for predi

77 ng Acute-Phase Retinopathy of Prematurity (e-ROP) Study telemedicine system of remote fundus image gr

78 ng Acute-Phase Retinopathy of Prematurity (e-ROP) study was conducted from May 1, 2011, to October 31

79 of Acute-Phase Retinopathy of Prematurity (e-ROP) study.

80 proaches to Evaluating of Acute-Phase ROP (e-ROP) Study.

81 ons when the risk cut point is surpassed), e-ROP IMAGING (trained reader grading of type 1 or 2 ROP i

82 was a post hoc analysis of a cohort in the e-ROP Study (a multicenter prospective telemedicine study)

83 Participants in the e-ROP Study were premature infants with a birth weight les

84 In the e-ROP study, 246 infants (492 eyes) were included in the a

85 had an IOH in an eye on at least 1 of the e-ROP visits.

86 (907 g [205 g], 27.4 weeks [2.2 weeks]) to e-ROP (864 g [212 g], 27.0 weeks [2.2 weeks]), with an inc

87 3 weeks CRYO, 34.1 weeks ETROP, 34.8 weeks e-ROP).

88 OP, 184 infants had 730 examinations; with e-ROP IMAGING, 242 infants had 532 imaging sessions, and 9

89 flect more accurately the behavior of expert ROP clinicians and may better standardize classification

90 Six participating expert ROP clinician-scientists, each with a minimum of 10 year

91 mmetrical findings were present in 71.4% for ROP stage 3 or above, 56.8% for zone I ROP, 50.0% for pl

92 sed to analyze the intragrader agreement for ROP diagnosis by the ophthalmologists-in-training during

93 for research, teaching, and patient care for ROP and suggests that a continuous ROP plus disease seve

94 basis for the within subject comparison for ROP trials.

95 with concurrent diagnostic examinations for ROP.

96 an readers graded each eye independently for ROP features in a 5 retinal-image set from each session.

97 regarding the role of mosaic photography for ROP telemedicine diagnosis.

98 ribe the characteristics of eyes at risk for ROP to provide insights into what types of ROP are most

99 included 7483 premature infants at risk for ROP with a known ROP outcome.

100 ticipants were premature infants at risk for ROP with a known ROP outcome.

101 d prospectively from all babies screened for ROP at 1 of 6 major ROP centers whose parents provided i

102 ctions in the number of infants screened for ROP without failing to identify infants requiring treatm

103 A tele-education system for ROP education was effective in improving the diagnostic

104 Intravitreal bevacizumab therapy for ROP is associated with more rapid outer retinal thickeni

105 charts to identify all patients treated for ROP milder than type 1.

106 evelopmental effects after anti-VEGF use for ROP treatment.

107 tal Growth and Retinopathy of Prematurity (G-ROP) Study (a multicenter retrospective cohort study).

108 tal Growth and Retinopathy of Prematurity (G-ROP) Study.

109 The G-ROP Study enrolled all infants undergoing ROP examinatio

110 s from all sessions, 412 (33.4%) infants had ROP stage 3 or above, 148 (12.0%) had zone I ROP, 70 (5.

111 es (86.0%) (P = .08); the presence of zone I ROP was detected in 57 of 191 (29.8%) early eyes vs 64 o

112 iews (90.0%) agreed with readers that zone I ROP was present, 23 of 40 (57.5%) agreed with readers th

113 of stage 3 or above, plus disease, or zone I ROP), and severity of ROP.

114 % for ROP stage 3 or above, 56.8% for zone I ROP, 50.0% for plus disease, and 73.7% for RW-ROP.

115 ROP stage 3 or above, 148 (12.0%) had zone I ROP, 70 (5.7%) had plus disease, and 419 (33.9%) had RW-

116 rral-warranted (RW) ROP (stage 3 ROP, zone I ROP, plus disease) on diagnostic examination from the Te

117 Accuracy of plus disease diagnosis by the i-ROP computer-based system was highest (95%; 95% CI, 94%-

118 Diagnostic accuracy of the i-ROP system (95%) was comparable to that of 11 expert phy

119 sure was the percentage of accuracy of the i-ROP system classification of plus disease, with the RSD

120 The i-ROP system was able to model this continuous severity wi

121 verity score, such as that provided by the i-ROP system, may improve agreement on disease severity in

122 s' postmenstrual age and followed up only if ROP was present at that examination, all type 1 ROP case

123 dictive model are 2 approaches for improving ROP screening efficiency.

124 ivation in response to auxin is abolished in ROP-deficient rop2 rop6 ROP4 RNAi plants.

125 d readers showed good inter-eye agreement in ROP characteristics, consistent with the high inter-eye

126 sistent with the high inter-eye agreement in ROP from clinical examinations by ophthalmologists in ot

127 al and supports within subject comparison in ROP trials.

128 has the potential to increase competency in ROP diagnosis and management for ophthalmologists-in-tra

129 The most common area of discrepancy in ROP classification is stage, although inter-expert agree

130 classification of images of plus disease in ROP.

131 The BW and GA of infants enrolled in ROP studies in the United States have decreased over the

132 Experts in ROP appear to consider findings from beyond the posterio

133 L-1beta as a potential therapeutic target in ROP.

134 a birth weight less than 1251 g and a known ROP outcome enrolled between May 25, 2011, and October 3

135 nts undergoing ROP examinations with a known ROP outcome who were born between January 1, 2006, and D

136 emature infants at risk for ROP with a known ROP outcome.

137 emature infants at risk for ROP with a known ROP outcome.

138 all babies screened for ROP at 1 of 6 major ROP centers whose parents provided informed consent.

139 of polymers, P(MBL)VAP, P(MBL)CLP, and P(MBL)ROP, can be readily controlled by adjusting the catalyst

140 l might be used reliably to guide a modified ROP screening schedule and decrease the number of examin

141 ico and the United States, an ideal national ROP screening and treatment program was highly cost-savi

142 tive in improving the diagnostic accuracy of ROP by ophthalmologists-in-training in Mexico.

143 The accuracy of ROP diagnosis (e.g., plus disease, zone, stage, category

144 t improvements (P < 0.01) in the accuracy of ROP diagnosis for plus disease, zone, stage, category, a

145 anisms by which ABA controls the behavior of ROP/RACs have remained unclear.

146 zumab (Case 1) and compare it with a case of ROP without treatment (Case 2), a case of a premature ba

147 presented with image-based clinical cases of ROP during a pretest, posttest, and training chapters.

148 f plus disease, zone, stage, and category of ROP after completion of the educational intervention.

149 ld retinal image sets for characteristics of ROP, pre-plus/plus disease, and retinal hemorrhage.

150 evidence that image-based classification of ROP reliably detects clinically significant levels of RO

151 een maternal diabetes and the development of ROP and type 1 ROP, adjusting for multiple risk factors.

152 To characterize discrepancies in findings of ROP between digital retinal image grading and examinatio

153 3), and a case of a baby without history of ROP or prematurity (Case 4).

154 included preterm children with a history of ROP who had undergone laser therapy.

155 6 to classify 34 wide-field fundus images of ROP as plus, pre-plus, or normal, coded as "3," "2," and

156 bly detects clinically significant levels of ROP with high accuracy compared with the clinical examin

157 The diagnosis and management of ROP has changed over the past 40 years; the role of anti

158 otographs on the diagnosis and management of ROP.

159 ough phosphorylation-dependent modulation of ROP activity.

160 ed widely to reduce the burdensome number of ROP screening examinations.

161 The occurrence of ROP was related to maternal preeclampsia in the full coh

162 Reactivation or persistence of ROP, as determined by clinical examination, fundus photo

163 (67% vs. 48%; P = 0.04) and the presence of ROP (96% vs. 91%; P < 0.01).

164 required lensectomy owing to progression of ROP and/or presence of lens opacity, then the hazard of

165 The rate of ROP (78.2% in case group and 14.7% in control group) and

166 me for these articles included recurrence of ROP and the need for retreatment (3 articles), retinal s

167 restricted cohort but with a reduced risk of ROP among a restricted subcohort of P-VLBW infants.

168 ciation of maternal preeclampsia and risk of ROP among infants in an unrestricted birth cohort and a

169 rences, the association of a reduced risk of ROP among the P-VLBW subcohort also may reflect biases f

170 el was applied weekly to predict the risk of ROP.

171 repository of over 2500 unique image sets of ROP.

172 < 0.0001) with the presence and severity of ROP (BW and GA adjusted odds ratios [ORs] of 2.46 for an

173 orrelated with both presence and severity of ROP and inversely correlated with BW and GA, although in

174 lus disease, or zone I ROP), and severity of ROP.

175 for RW-ROP, and 72.7% (0.63) for severity of ROP.

176 ty to screen remote areas with a shortage of ROP providers, thereby reducing the burden of disease.

177 tational age at birth, birthweight, stage of ROP at presentation, prior treatment (laser or cryothera

178 en paired eyes was 75.3% (0.65) for stage of ROP, 82.3% (0.68) for zone of ROP, 78.7% (0.51) for plus

179 The association with advanced stages of ROP is a concern and needs to be further explored in lar

180 images in 4 neonates with various stages of ROP that were obtained using a prototype handheld device

181 [range, 34-43 weeks]) with various stages of ROP: 3 in the neonatal intensive care unit and 1 in the

182 e therapy in the prevention and treatment of ROP.

183 r ROP to provide insights into what types of ROP are most easily detected early by image grading.

184 ) for stage of ROP, 82.3% (0.68) for zone of ROP, 78.7% (0.51) for plus disease, 84.7% (0.56) for RW-

185 Additional research is needed to optimize ROP predictive model development, validation, and applic

186 n to stage 4 ROP (3 eyes, 23.1%); persistent ROP at an advanced postmenstrual age (4 eyes, 30.8%); an

187 cine Approaches to Evaluating of Acute-Phase ROP (e-ROP) Study.

188 r treatment with bevacizumab for acute-phase ROP than after laser.

189 that MPK1 interacts with and phosphorylates ROP BINDING PROTEIN KINASE 1 (RBK1), a protein kinase th

190 e, we show that both auxin and Rho-of-Plant (ROP) signaling modulate polar nuclear position at the in

191 members of the Rho-like GTPases from Plants (ROP) small GTPase family.

192 early 1990s by ring-opening polymerisation (ROP) of silicon-bridged [1]ferrocenophanes (sila[1]ferro

193 Ring-opening polymerization (ROP) is a powerful synthetic methodology for the chemica

194 Ring-opening polymerization (ROP) of an allyl-substituted caprolactone monomer was ca

195 witched between ring-opening polymerization (ROP) of BBL and CHO/CO2 copolymerization by the presence

196 aterials is the ring-opening polymerization (ROP) of cyclic monomers.

197 talyst for both ring-opening polymerization (ROP) of lactones and ring-opening copolymerization (ROCO

198 organocatalyzed ring-opening polymerization (ROP) of rac-lactide (rac-LA).

199 ich can undergo ring-opening polymerization (ROP) to prepare poly(alpha-hydroxyalkanoic acid) with fu

200 e, stage, category, and aggressive posterior ROP (AP-ROP).

201 d into stage 3+ ROP and aggressive posterior ROP [APROP]) in zone I or zone II posterior who received

202 with zone I disease or aggressive posterior ROP), the disadvantages are that the ROP recurrence rate

203 were treated for retinopathy of prematurity (ROP) (ROP-Tx group); those with spontaneously regressed

204 plus disease in retinopathy of prematurity (ROP) by experts.

205 ic competency in retinopathy of prematurity (ROP) by ophthalmologists-in-training in Mexico.

206 the treatment of retinopathy of prematurity (ROP) compared with laser photocoagulation therapy.

207 fellow eyes for retinopathy of prematurity (ROP) features (stage, zone and plus disease) and severit

208 Telemedicine in retinopathy of prematurity (ROP) has the potential for delivering timely care to pre

209 Retinopathy of prematurity (ROP) is a leading cause of childhood blindness worldwide

210 Retinopathy of prematurity (ROP) is one of the targets for early detection and treat

211 Retinopathy of prematurity (ROP) is the leading cause of childhood blindness, but cu

212 inopathie (DR), retinopathie of prematurity (ROP) or the retinal vein occlusion (RVO) are caused thro

213 fants undergoing retinopathy of prematurity (ROP) screenings.

214 n a patient with retinopathy of prematurity (ROP) treated with ranibizumab (Case 1) and compare it wi

215 severe stages of retinopathy of prematurity (ROP) were found among CMV-infected infants (adjusted RR,

216 and severity of retinopathy of prematurity (ROP) were investigated by univariate and multivariate an

217 linical care for retinopathy of prematurity (ROP), but little information exists regarding the role o

218 to treat type 1 retinopathy of prematurity (ROP), but there remain concerns about systemic toxicity.

219 opathies such as retinopathy of prematurity (ROP), diabetic retinopathy (DR) and retinal vein occlusi

220 with or without retinopathy of prematurity (ROP).

221 he management of retinopathy of prematurity (ROP).

222 lation in type 1 retinopathy of prematurity (ROP).

223 preeclampsia and retinopathy of prematurity (ROP).

224 atment-requiring retinopathy of prematurity (ROP).

225 gery in advanced retinopathy of prematurity (ROP).

226 e risk of severe retinopathy of prematurity (ROP).

227 ed to the educational intervention (pretest, ROP tutorial, ROP educational chapters, and posttest), a

228 ified as part of a multicenter, prospective, ROP cohort study from 7 participating centers.

229 isk period, and characteristics of recurrent ROP.

230 The clinical observation of reduced ROP severity in premature infants after caffeine treatme

231 x group); those with spontaneously regressed ROP (ROP-non-Tx group); other premature patients (premat

232 covariate adjustment were applied to relate ROP to preeclampsia among the full cohort and in a subco

233 ned after adjustment for treatment-requiring ROP (odds ratio, 0.72; 95% CI, 0.58-0.91 for each 1-week

234 Treatment-requiring ROP was a stronger impact factor than GA on visual impai

235 When treatment-requiring ROP was adjusted for, no significant association between

236 model's sensitivity for treatment-requiring ROP.

237 up); those with spontaneously regressed ROP (ROP-non-Tx group); other premature patients (premature g

238 reated for retinopathy of prematurity (ROP) (ROP-Tx group); those with spontaneously regressed ROP (R

239 Routine ROP screening was conducted from June 29, 2011, to Octob

240 zed images that were obtained during routine ROP screening in neonatal intensive care units.

241 nalysis of eyes with referral-warranted (RW) ROP (stage 3 ROP, zone I ROP, plus disease) on diagnosti

242 y eyes (153 [80.1%]) interpreted as being RW-ROP positive on imaging evaluation agreed with examinati

243 vity of the telemedicine system to detect RW-ROP.

244 stational age, 24.8 [1.4] weeks) detected RW-ROP earlier than diagnostic examination (early) in 191 (

245 42.7%) eyes by about 15 days and detected RW-ROP in 123 infants (mean [SD] gestational age, 24.6 [1.5

246 Time of detecting RW-ROP on image evaluation compared with clinical examinati

247 n the examination subsequently documented RW-ROP.

248 In most early RW-ROP eyes, the findings were consistent with clinical exa

249 repant image and examination findings for RW-ROP components.

250 r any ROP, 2.88 for stage 3, and 3.19 for RW-ROP).

251 (0.51) for plus disease, 84.7% (0.56) for RW-ROP, and 72.7% (0.63) for severity of ROP.

252 OP, 50.0% for plus disease, and 73.7% for RW-ROP.

253 7%) had plus disease, and 419 (33.9%) had RW-ROP in one or both eyes; symmetrical findings were prese

254 A total of 447 eyes had RW-ROP on diagnostic examination.

255 s (95% CI, 67.3-72.8) for the presence of RW-ROP.

256 OP determined a significant proportion of RW-ROP; plus disease played a relatively minor role.

257 tem for detecting referral-warranted ROP (RW-ROP) were calculated with and without incorporating hemo

258 tage, zone, plus, referral-warranted ROP (RW-ROP, defined as presence of stage 3 or above, plus disea

259 At the sessions in which RW-ROP was first found by examination, stage 3 or more in 1

260 are to premature infants at risk for serious ROP.

261 for identifying children who develop severe ROP using telemedicine and a predictive model synergisti

262 at was lower than previously used for severe ROP, was effective in this study, and could be tested in

263 ent screening has low specificity for severe ROP.

264 Moderately severe ROP (defined as prethreshold or referral warranted) vari

265 Patients with more severe ROP had a higher incidence of glaucoma after lens-sparin

266 iates imaging, and imaging finding of severe ROP initiates diagnostic examinations).

267 or each image set used, a reference standard ROP diagnosis was established by combining the clinical

268 EcROP demonstrates that ROP screening and treatment is highly beneficial for qua

269 he control group, trainees who completed the ROP tele-education system performed better on the postte

270 Organocatalysts for the ROP of OCAs, such as dimethylaminopyridine (DMAP), may i

271 ows a hitherto unknown high activity for the ROP of rac-lactide at room temperature.

272 es of errors occurred more frequently in the ROP-Tx group than in the full-term group (all P < .05).

273 The eyes of the ROP children also exhibited steeper corneas, shallower a

274 The eyes of the ROP children exhibited a narrower ACA, steeper iris curv

275 The eyes of the ROP children presented a narrower ACA and a more anterio

276 e was the sensitivity and specificity of the ROP diagnosis by experts that was calculated using a con

277 ast frequently identified in patients of the ROP-Tx group (65.2% and 47.8%, P = .002 and P < .001, re

278 Small GTPases of the ROP/RAC family act as negative regulators of ABA signal

279 Here we report that the ROP of gamma-BL can, with a suitable catalyst, proceed s

280 sterior ROP), the disadvantages are that the ROP recurrence rate is higher, and vigilant and extended

281 es focused on ablative therapy for threshold ROP, earlier treatment for type 1 or pre-threshold disea

282 To describe a tiered approach to ROP screening (TARP) for identifying children who develo

283 The tiered approach to ROP screening was associated with a reduced number of ex

284 Image findings predicted TR-ROP better than GA (area under receiver operating charac

285 Risk score >/=3 points for predicting TR-ROP had a sensitivity of 98.8%, specificity of 40.1%, an

286 Risk score points for predicting TR-ROP were derived from the regression coefficients of sig

287 Treating ROP with intravitreal bevacizumab results in a character

288 ational intervention (pretest, ROP tutorial, ROP educational chapters, and posttest), and 29 of 58 tr

289 G-ROP Study enrolled all infants undergoing ROP examinations with a known ROP outcome who were born

290 cine system for detecting referral-warranted ROP (RW-ROP) were calculated with and without incorporat

291 ) for stage, zone, plus, referral-warranted ROP (RW-ROP, defined as presence of stage 3 or above, pl

292 mean [SD] gestational age, 24.8 [1.4] weeks) ROP was noted earlier on image evaluation in 151 of 191

293 ve decreased over the past 27 years, whereas ROP prevalence and onset of disease are stable.

294 examined 54 eyes of 29 preterm children with ROP and 134 eyes of 67 children born at term.

295 cademic medical center among 4 neonates with ROP in the neonatal intensive care unit and in the opera

296 e-field OCT and OCTA images in neonates with ROP using a prototype handheld OCT and OCTA device.

297 m) OCTA scans were obtained in patients with ROP in a single 2-second scan.

298 (Case 2), a case of a premature baby without ROP (Case 3), and a case of a baby without history of RO

299 preterm infants with GA </= 28 weeks without ROP and 14/55 (26%) with GA </= 32 weeks with retinopath

300 preterm-infants with GA 29-32 weeks without ROP, 13/59 (22%) preterm infants with GA </= 28 weeks wi